With the prospect that even more innovative drug therapies will be introduced in the coming years, society is demanding new approaches to comparative risk/benefit evaluation, as well as new concepts. Such evaluations are usually carried out only once the relevant therapies have been used widely in daily practice. The safety and risk management assessment of different drug therapies is then performed within the framework of observational epidemiological studies (e.g. to establish proof of ‘safety’ and proof of ‘effectiveness’). This is the logical next step after randomized clinical trials, which are designed to provide evidence of a drug’s ‘efficacy’. During this Pharmacoepidemiology and Drug Safety course, you will learn about typical problems, (such as confounding by indication, or rare side effects) and various pharmacoepidemiologic approaches to dealing with these problems.
The course will cover key issues in pharmacoepidemiologic and drug safety research. Special topics you will discuss include adjustment for confounding, risk detection and management, molecular pharmacoepidemiology and public health.
By the end of this pharmacoepidemiologic and drug safety course, you will be able to:
- Broaden your understanding of pharmacological study design issues and methods
- Explain confounding and other biases, including the indication-related methods of adjusting for confounding
- Distinguish between different methods of drug safety research
- Describe the principles of drug safety and risk management
- Have an overview of the role of pharmacoepidemiological databases
- Understand the essence of molecular pharmacoepidemiology
- Have insight into drug utilization research
Olaf Klungel MSc PhD
Dr. Olaf Klungel is Associate Professor at the division of Pharmacoepidemiology & Clinical Pharmacology at Utrecht University. He was trained as a pharmacist and epidemiologist. His main research area is the development, improvement and evaluation of innovative methods in causal drug research. Main applications are in cardiovascular pharmacoepidemiology with a focus on methodology to assess the effects of cardiovascular drug therapy in daily clinical practice.